SciClone Pharmaceuticals, Inc. (SCLN) China Market Penetration Strategy Pays Off in Earnings

SciClone Pharmaceuticals is a U.S.-based specialty pharma company with 15 products currently in the market. The company’s lead product, ZADAXIN® is approved in more than 30 countries for the treatment of hepatitis B, hepatitis C, as a vaccine adjuvant, and certain cancers.

While SciClone’s sales representatives fan throughout China, Asia, and Latin America, the company focuses primarily on China while seeking entrance into emerging markets through in-licensing agreements, similar to those currently held with Sanofi Aventis, Baxter, Pfizer, and Iroko.

In the first quarter of 2012, SciClone received approval of Tramadol® to treat moderate-to-severe pain. On deck are plans to advance DC Bead, the company’s next product lined up to potentially receiving approval.

SciClone has topped its earnings estimates for the last four quarters, and in the second quarter of 2012 reported earnings of $0.20 per share, a penny increase over EPS of $0.19 the year prior.

Revenues for the quarter came in at $40.3 million, an increase of 22% compared to revenues of $33.1 million for the second quarter of 2011, reflecting strength in sales of its ZADAXIN®, primary care and oncology business in China, and the inclusion of NovaMed Pharmaceuticals, which it acquired in April 2011.

For more information visit www.sciclone.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html